Université de Lyon, Lyon, France.
Med Microbiol Immunol. 2015 Aug;204(4):493-504. doi: 10.1007/s00430-014-0360-3. Epub 2014 Oct 26.
Some bacterial species recovered from the airways of cystic fibrosis (CF) patients are indisputably associated with lung infections, whereas the clinical relevance of others, such as Nocardia spp., remains unclear. Sixteen French CF cases of colonization/infection with Nocardia spp. were reviewed in order to evaluate the epidemiology, the clinical impact and the potential treatment of these bacteria, and results were compared to those of the literature. Five Nocardia species were identified, Nocardia cyriacigeorgica being the major species (50 % of cases). At first isolation, Nocardia was the sole pathogen recovered in six patients. Seven patients presented pulmonary exacerbation. For 12 patients, antimicrobial treatment against Nocardia was started immediately, mainly based on cotrimoxazole (6 of the 12 cases). In this study, we highlight the heterogeneity of the clinical management of Nocardia spp. in CF. Guidelines for the clinical management of Nocardia infections in CF patients are proposed.
从囊性纤维化 (CF) 患者气道中分离出的一些细菌与肺部感染密切相关,而其他细菌(如诺卡氏菌属)的临床相关性尚不清楚。本文回顾了法国 16 例 CF 患者诺卡氏菌属定植/感染病例,以评估这些细菌的流行病学、临床影响和潜在治疗方法,并与文献进行了比较。共鉴定出 5 种诺卡氏菌,其中主要为触须诺卡氏菌 (50%的病例)。首次分离时,6 例患者仅分离出诺卡氏菌,7 例患者出现肺部恶化。12 例患者立即开始针对诺卡氏菌的抗菌治疗,主要使用复方磺胺甲噁唑(12 例中有 6 例)。本研究强调了 CF 患者中诺卡氏菌属的临床管理存在异质性。本文提出了 CF 患者诺卡氏菌感染的临床管理指南。